Original article
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis
La prevalencia de cáncer en pacientes con esclerosis múltiple (EM) que recibieron rituximab: una revisión sistemática y meta-análisis
O. Mirmosayyeba, V. Shaygannejada, N. Ebrahimia, H. Ghoshounia, M. Ghajarzadehb,
Corresponding author
a Department of Neurology, School of Medicine, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
b Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Read
1994
Timeswas read the article
444
Total PDF
1550
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 31 | 7 | 38 |
| 2025 11 | 139 | 68 | 207 |
| 2025 10 | 89 | 19 | 108 |
| 2025 9 | 85 | 38 | 123 |
| 2025 8 | 80 | 32 | 112 |
| 2025 7 | 73 | 16 | 89 |
| 2025 6 | 59 | 9 | 68 |
| 2025 5 | 72 | 10 | 82 |
| 2025 4 | 70 | 17 | 87 |
| 2025 3 | 50 | 9 | 59 |
| 2025 2 | 37 | 16 | 53 |
| 2025 1 | 58 | 14 | 72 |
| 2024 12 | 40 | 6 | 46 |
| 2024 11 | 34 | 11 | 45 |
| 2024 10 | 30 | 10 | 40 |
| 2024 9 | 32 | 7 | 39 |
| 2024 8 | 36 | 7 | 43 |
| 2024 7 | 31 | 1 | 32 |
| 2024 6 | 40 | 15 | 55 |
| 2024 5 | 19 | 8 | 27 |
| 2024 4 | 47 | 3 | 50 |
| 2024 3 | 50 | 8 | 58 |
| 2024 2 | 63 | 8 | 71 |
| 2024 1 | 32 | 4 | 36 |
| 2023 12 | 33 | 8 | 41 |
| 2023 11 | 53 | 18 | 71 |
| 2023 10 | 51 | 14 | 65 |
| 2023 9 | 15 | 4 | 19 |
| 2023 8 | 17 | 3 | 20 |
| 2023 7 | 6 | 11 | 17 |
| 2023 6 | 14 | 2 | 16 |
| 2023 5 | 40 | 4 | 44 |
| 2023 4 | 24 | 2 | 26 |
| 2023 3 | 0 | 3 | 3 |
| 2023 2 | 0 | 9 | 9 |
| 2023 1 | 0 | 5 | 5 |
| 2022 12 | 0 | 4 | 4 |
| 2022 11 | 0 | 12 | 12 |
| 2022 10 | 0 | 2 | 2 |
Show all
